Chemical Structure (Jardiance 01)
Jardiance Tablet, Film Coated
Product Images NDC 50090-6457
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Jardiance (NDC 50090-6457). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Jardiance 02)
This appears to be a list of medication names with their recommended dosage and frequency. However, there is also a section at the bottom with a mix of letters and numbers that is not clear enough to determine what it represents.*
Figure 2 (Jardiance 03)
Figure 3 (Jardiance 04)
This is a chart showing the mean change from baseline in HbA1C (%) for patients taking placebo, empagliflozin 10mg, and empagliflozin 25mg. The chart is divided into different time periods (baseline, 6 weeks, 12 weeks, 18 weeks, and 24 weeks) and indicates that empagliflozin resulted in a greater reduction in HbA1C compared to placebo. The results are adjusted for baseline HbA1C, geographical region, and oGFR.*
Figure 4 (Jardiance 05)
This is a clinical data table comparing the mean change from baseline HbA1c levels of Glimepiride + Metformin and Empagliflozin 25mg + Metformin in a study consisting of 700 and 693 individuals, respectively. The table shows data for various weeks up to 52 weeks. The mean change from baseline is adjusted for baseline HbA1c, geographic region and eGFR at baseline.*
Figure 5 (Jardiance 06)
This table appears to show the percentage of patients experiencing an event (not specified) over time in a study comparing a placebo group to a group taking Empaglifiozin, with the number of subjects at risk for each time point listed. The table has no header or context, so it is not possible to provide a more specific description of the study or results.*
Figure 6 (Jardiance 07)
Qr Code (Jardiance 08)
Figure 7 (Jardiance 08a)
This appears to be a table or graph displaying the incidence of a function, possibly related to Empaglifiozin 10 mg compared to a placebo group, with various p-value and HR (hazard ratio) values. The chart also includes a list of patients at risk and days since randomization.*
Figure 8 (Jardiance 08b)
Figure 9 (Jardiance 08c)
This text appears to be a statistical table evaluating the effectiveness of a medication called Empagifiozin 10mg versus a placebo for people with diabetes and different baseline health conditions, including heart failure physiology and GFR at baseline. It also includes statistics on the participants' demographics, such as sex, race, and BMI. The table measures the Hazard ratio, which assesses the risk of an event (such as death or hospitalization) occurring in the treatment group compared to the control group.*
Figure 10 (Jardiance 08d)
Figure 11 (Jardiance 08e)
This appears to be a table or graph displaying data for a comparison between placebo and a medication called Empagliflozin 10 mg in a study involving 2991 and 2997 participants, respectively. The data seems to show the mean number of events observed, and indicates that the medication had a statistically significant effect compared to placebo based on a hazard ratio, confidence intervals, and p-value. The table also shows the number of patients at risk and days since randomization for both groups.*
Figure 12 (Jardiance 08f)
This text appears to be a statistical table with various categories, subgroups, and numerical values related to a medical study. It includes information about a medication called Empagifiozin 10mg, compared to a placebo, for the treatment of diabetes. The table also contains data on demographics, baseline health conditions, and medication use of the participants.*
Label Image (Lbl500906457)
This is a medication description for product number 9842-0, which contains 90 tablets of Empagliflozin (25mg each). The text also includes some seemingly random characters that are not recognizable.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
